Applications of 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT) in Industrial Manufacturing

3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT) supports multiple advanced chemical synthesis processes, primarily in life sciences and specialty materials manufacturing. As an established peptide coupling reagent and condensation agent, it provides unique performance in peptide production, pharmaceutical intermediates, research chemicals, and custom oligonucleotide synthesis. This section details application pathways based on real downstream industry demand, including compliance standards, incorporation into formulations, processing integration, and the corresponding end-use products delivered by customers.

1. Peptide Synthesis for Pharmaceutical APIs

As a coupling agent, DEPBT enables carbodiimide-free peptide bond formation that minimizes racemization, supporting the manufacture of high-purity pharmaceutical active ingredients. Operators prefer DEPBT in solid-phase and solution-phase peptide synthesis, where high sequence fidelity and low by-product profiles are critical for regulated medicinal use. Its performance supports both small molecule APIs and complex peptide drugs in scalable GMP environments.

Industry compliance standards

• ICH Q7A: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• USP & EP General Chapters for Peptide APIs
• 21 CFR 210/211: FDA cGMP Regulations
• ISO 9001:2015 Quality Management Systems

Typical usage ratio

• 0.9–1.2 equivalents per carboxyl group in peptide coupling reactions; specific ratio adapted to peptide sequence length and resin loading for SPPS applications.

Downstream process integration

• Reagent added during amino acid activation stage on resin in solid-phase peptide synthesis (SPPS) or dissolved in DMF/DCM solution for bulk solution-phase couplings; introduced prior to amine addition to initiate coupling cycle.

Final product types

• Synthetic peptide pharmaceuticals (e.g., somatostatin analogs, leuprolide, oxytocin)
• Generic peptide drug substances for regulated markets
• Custom NCE (new chemical entity) peptide APIs
• Research-grade peptide reference standards

2. Manufacture of Pharmaceutical Intermediates

Chemical manufacturers utilize DEPBT to facilitate amide bond formation or introduce peptide-like linkages in key intermediates for drugs where other coupling chemistries are unsuitable. This approach yields higher selectivity and limits side reaction products during scale-up, essential for intermediates moving into API processing under regulatory inspection.

Industry compliance standards

• ICH Q11: Development and Manufacture of Drug Substances
• EU GMP Part II: Basic Requirements for Active Substances
• REACH Regulation (EC) No 1907/2006 (chemical safety for intermediates)
• ISO 14001 Environmental Management (waste control in intermediate synthesis)

Typical usage ratio

• 1.0–1.1 molar equivalent to activated carboxylic component, adjusted for substrate reactivity and desired process throughput.

Downstream process integration

• Incorporated into batch reactors immediately before addition of nucleophilic amine intermediates; used at elevated or controlled temperatures to ensure full conversion before workup and purification.

Final product types

• Benzotriazine- or amide-containing pharma intermediates
• Building blocks for synthetic penem and carbapenem antibiotics
• Key intermediates for peptide hormone analogs
• Protected amino acid derivatives for further transformations

3. Custom Peptide Synthesis for Diagnostic and Research Products

Producers of research and diagnostic reagents use DEPBT in custom peptide synthesis workflows, where sequence specificity, rapid cycle times, and minimized epimerization are essential. The material’s high activation reactivity and reduced generation of by-products facilitate efficient assembly of short- and medium-length peptides, especially for use in ELISA kits, proteomics, and bioanalytical platforms.

Industry compliance standards

• ISO 13485: Medical Devices – Quality Management Systems
• OECD Principles of Good Laboratory Practice (GLP)
• FDA QSR (21 CFR Part 820) for diagnostic device components

Typical usage ratio

• 0.95–1.1 molar equivalent relative to carboxy moiety for short peptide assembly; ratio tailored by lab according to resin substitution and final peptide length.

Downstream process integration

• Introduced at each coupling cycle during automated and manual solid-phase peptide synthesis in multi-well format or benchtop reactors; purged after each step prior to washing and deprotection cycles.

Final product types

• Diagnostic ELISA peptide antigens
• Proteomics standard peptides
• Peptide probes for screening assays
• Custom research peptides (mg/g scale)

4. Oligonucleotide and PNA (Peptide Nucleic Acid) Synthesis

Specialty contract manufacturers deploy DEPBT to improve the coupling efficiency in both oligonucleotide and PNA synthesis workflows, where side reactions and incomplete conjugation can greatly affect purity. Its compatibility with phosphoramidite chemistry allows for higher yields in DNA- or peptide-based molecular tools, vital for genomics, antisense therapeutics, and molecular diagnostics industries.

Industry compliance standards

• USP <1045>/EP 2.6.30 Nucleic Acid-based Drugs Guidance
• GMP for Active Substance Manufacturers (EU/ICH/FDA)
• ISO 18385: Minimizing risk of DNA contamination
• ISO 9001 Quality Management for Oligonucleotide Production

Typical usage ratio

• 1.0–1.05 molar equivalent per condensation step in PNA backbone and mixed peptide-nucleotide assemblies; adjusted based on chain length, target purity, and scale.

Downstream process integration

• Added during stepwise chain elongation on solid support in automated synthesizers for PNA/DNA conjugation; follows deprotection and capping stages in multistep protocols.

Final product types

• Synthetic PNA oligomers for research and therapeutic use
• Fluorescently labeled DNA peptide conjugates for molecular diagnostics
• siRNA and antisense oligonucleotide intermediates
• PNA-based biosensors and gene probes

5. Production of Specialty Peptide-Based Coating Additives

DEPBT serves in the functionalization of select peptide derivatives, which are then incorporated as performance additives in specialty coatings. These peptides, produced via efficient DEPBT-mediated couplings, enhance binding and durability in protective films and microelectronic material layers.

Industry compliance standards

• ISO 22196: Antibacterial activity on plastics and non-porous surfaces
• IEC 61010-1: Safety requirements for electrical equipment (for microelectronics coatings)
• RoHS Directive (2011/65/EU) for restricted substances
• ISO 9001:2015 in specialty chemical production

Typical usage ratio

• 1.0–1.2 equivalents based on functional group loading during peptide synthesis; varies according to peptide-modified coating additive concentration required in formulation (typically 0.5–2% w/w in final coating).

Downstream process integration

• Applied in batch synthesis of peptide-functionalized intermediates, which undergo final purification and are then dispersed into aqueous or solvent-based coating matrices prior to film casting or spraying.

Final product types

• Antimicrobial or anti-static coating additives for electronics
• Surface binding peptides for specialty glass or metal coatings
• Biofunctional polymer additives for advanced packaging films